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Abstract
Background: We hypothesized that the relative proportion of tumor (PoT) at the 
luminal surface can predict gastric cancer (GC) patient survival.
Methods: We measured the luminal PoT in resection specimens from 231 GC pa-
tients with stage II/III disease who had surgery at the Kanagawa Cancer Center, 
Yokohama, Japan. Tissue microarrays were used to assess the extent of immune cell 
infiltration by CD45 immunohistochemistry. Results were related to histopathologi-
cal features and patient overall survival (OS).
Results: PoT was significantly lower in diffuse- type (30%) compared to intestinal- 
type GC (41%), P = 0.03. Patients with low PoT intestinal- type GC survived signifi-
cantly longer than patients with high PoT intestinal- type GC (5 years OS: 78% vs 
47%, P = 0.0112). Low PoT was an independent favorable prognostic factor in mul-
tivariate analysis in intestinal- type GC. Low PoT was correlated with high content of 
CD45- positive immune cells (P = 0.035). There was no relationship between PoT 
and survival in diffuse- type GC.
Conclusions: This is the first study to identify a subgroup of patients with stage II/
III intestinal- type GC at high risk of recurrence by measuring PoT at the luminal 
surface. The relationship between PoT and immune cell content provides an initial 
insight into potential underlying biological mechanisms.
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1 |  INTRODUCTION
Gastric cancer (GC) is the fourth most common malignant 
disease and the second most frequent cause of cancer- related 
deaths worldwide.1 Complete resection is essential for the 
cure of localized gastric cancer.2 Patients with stage I disease, 
in which the tumor is limited to T1N0- 1 and T2N0, rarely 
develop a recurrence and have an excellent prognosis. Stage 
IV cancers are unresectable, and these patients have a very 
poor prognosis. On the other hand, GC patients with stage II/
III disease often have recurrent disease even after complete 
curative resection.3 At present, the standard treatment for lo-
cally advanced GC in Asia, Europe, and the United States is 
D2 gastrectomy followed by adjuvant chemotherapy, surgery 
combined with pre- and postoperative chemotherapy, or sur-
gery followed by postoperative chemoradiotherapy.4-7
In recent years, the tumor microenvironment has be-
come a focus of intense research, as alterations that occur 
in the stroma surrounding tumor cells or interactions be-
tween stroma and tumor cells might be related to patient 
prognosis and could represent potential new therapeutic 
targets.8,9 The tumor microenvironment contains cells (fi-
broblasts, inflammatory cells, endothelial cells forming 
vascular channels, mesenchymal stem cells) and noncel-
lular components such as extracellular matrix, deposited 
growth factors, and signaling molecules.10 Studies in se-
lected cancer subtypes have quantified the components of 
primary tumors and suggested that the tumor composition 
is associated with patient survival.11-13 Our own previous 
genomic meta- analysis identified a stromal gene expres-
sion signature as predictor of survival in gastric cancer.14 
At the same time, we could demonstrate using quantitative 
morphometry that a high intra- tumoral stroma content is 
related to poor survival in Caucasian GC patients which has 
been confirmed very recently by a study in Italian GC.15 
Two studies from Asian GC seem to suggest a similar re-
lationship between stroma content and survival. Data from 
the relative stroma content at the deep invasive tumor edge 
in Chinese GC was used to propose a “new” staging system 
combining tumor- stroma ratio and conventional TNM stag-
ing.16 The study in Korean GC restricted their evaluation of 
the tumor stroma content to areas with greatest proportion 
of stroma in a series of signet ring cancers reaching similar 
conclusions.17
In order to optimize patient management decisions, 
prognostic factors should ideally be measurable at the time 
of diagnosis, for example, in the diagnostic biopsy. The 
methodology we used in our own previous study or was 
used by the Italian, Chinese, and Korean investigators de-
pends on the availability of a resected specimen to select 
the area of interest for stroma evaluation.15-18 It is unclear 
whether a similar relationship between tumor stroma con-
tent and GC patient survival can be demonstrated when 
measurements are performed in material from the luminal 
surface of the tumor.
The aim of our study was to investigate whether the rela-
tive proportion of tumor (PoT) measured in an area of highest 
tumor density at the luminal surface of the tumor (eg, in an area 
typically targeted by endoscopic biopsies) can predict survival 
in Japanese patients with stage II/III gastric cancer and hence 
may serve as a potential biomarker to identify patients at high 
risk of recurrence already at the time of diagnosis.
2 |  MATERIALS AND METHODS
2.1 | Patients
The patients were selected from the prospective database 
of the Department of Gastrointestinal Surgery, Kanagawa 
Cancer Center, Yokohama, Japan, according to the following 
inclusion criteria; (a) histologically proven gastric adenocar-
cinoma, (b) patients underwent potentially curative D2 gas-
trectomy as primary treatment between June 2002 and March 
2010, and (c) pathologically confirmed stage II or III disease 
(TNM classification 7th ed and 14th edition of the general 
rules for gastric cancer published by the Japanese Gastric 
Cancer Association).19,20 A total of 231 patients fulfilled the 
inclusion criteria and were included in the current study. One 
hundred and six (45.9%) patients were treated by surgery 
alone, 104 (45.0%) by surgery followed by S- 1. 21 (9.1%) 
patients included in our study were recruited into the SAMIT 
trial and therefore received Tegafur/Uracil (UFT) adjuvant 
treatment. As adjuvant UFT treatment is not the standard ad-
juvant treatment for GC in JAPAN and the potential benefit 
of adjuvant UFT was uncertain at the time of our study, we 
excluded patients who received UFT for the survival analy-
ses. Patients were followed- up in the out- patient clinic. Blood 
tests and physical examination were performed at least every 
2 weeks in patients on adjuvant treatment, and at least every 
3 months after finishing S- 1 treatment for 5 years. Patients 
in the surgery- only group underwent similar examinations at 
least every 3 months. Patients had a computer tomography 
of the thorax and abdomen every 6 months during the first 
3 years after surgery and then annually until 5 years after 
surgery.
2.2 | Surgical procedure and 
pathological diagnosis
All patients had a  distal or total gastrectomy with lymph node 
(LN) dissection for gastric cancer. In principle, a D1 or a D1+ 
lymphadenectomy is indicated for cT1N0 tumors, and D2 is 
applied for cN+ or cT2- T4 tumors regardless of the approach. 
Spleen- preserving D2 total gastrectomy was permitted in this 
study.
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The resected stomach and all harvested LNs were fixed 
with 10% buffered formalin for at least 48 hours. After stan-
dard histopathological processing of the tissue, sections were 
cut from each block and stained with hematoxylin and eosin 
(H&E).
2.3 | Measurement of the relative 
proportion of tumor (PoT)
Slides from all resection specimens were retrieved from the ar-
chive and reviewed by expert gastrointestinal pathologists. The 
H&E slide with the highest tumor cell density and the deep-
est tumor infiltration was selected. Slides were scanned at ×40 
magnification with an automated scanning system (Aperio XT, 
Aperio Technologies, Vista, CA, USA) at the Slide Scanning 
Facility, LICAP, University of Leeds, UK. Using a digital slide 
viewer (Image Scope v8.0, Aperio Technologies), slides were 
reviewed and analyzed. A 9 mm2 area with highest tumor cell 
density on visual inspection was selected from the luminal sur-
face as a surrogate for tissue sampling by endoscopic biopsies. 
A grid with a systematic random sample of 300 points was su-
perimposed in the selected area using virtual graticule software 
(Random Spot, University of Leeds, Leeds, UK) to determine 
the relative proportion of the tumor components.21 Areas of 
necrosis and mucus at the surface were avoided when select-
ing the area (Figure 1). The following categories were used 
when evaluating the tissue at each measurement point: tumor, 
stroma, tumor lumen, necrosis, vessel, inflammation, and non-
informative (unclassifiable). One of the authors (ToruA) was 
trained by experienced GI pathologists (HG & TA) in recog-
nizing the different categories. All cases were scored by TA 
and ToruA blinded to the histopathological and survival data. 
To assess interobserver variation between experts, a random 
sample of 40 cases was also scored by a second GI pathologist 
(GH). PoT was expressed as a percentage fraction of tumor of 
the informative points per case. Each case took approximately 
20 minutes to score.
2.4 | Immunohistochemistry
After having obtained the results from the PoT measurement, 
we decided to expand our study and evaluate the overall 
extent of immune cell infiltration in the tumor hypothesiz-
ing that the extent of immune cell infiltration may provide 
some insights into the biology underlying our PoT results. 
Tissue microarrays (TMA) were constructed sampling two 
1.5- mm- diameter cores from the same tumor area as de-
scribed above as measurement area. Four micron sections 
were cut from each TMA block and manual immunohisto-
chemistry (IHC) was carried out as described previously.22 
Anti- CD45 (clone 2B11/PD7/26 from Dako Cytomation) 
was used to stain all leucocytes and used as surrogate to as-
sess the extent of immune cell infiltration in the tumor. A 
streptavidin biotin detection system (Dako REALTM Kit, 
Dako, Denmark) and 3,3′- Diaminobenzidine (DAB) were 
used according to the manufacturer’s instructions. Sections 
were counterstained with Mayer’s Haemalaun, dehydrated 
and coverslipped. Sections from a multi- tissue block served 
as positive and negative control.
2.5 | Scoring of CD45 immunohistochemistry 
using automated image analysis
CD45 stained slides were scanned at x40 magnification 
using an Aperio XT digital slide scanner. The in- house 
developed software system, Tissue MicroArray informat-
ics (TMAi), was used to de- array the digital images and 
assign the relevant identifiers to each core. Cores were 
individually analyzed using a custom- made MATLAB- 
based algorithm for the presence of foreground tissue 
stained brown with DAB based on the hue, saturation, and 
intensity (HSV) colour space. Detection thresholds were 
calculated per image as 0.5 standard deviation below the 
mean intensity of the staining channel. The percentage of 
positive pixels per core (Positive pixels/(positive pixels 
+ negative pixels)*100) was used as a surrogate for the 
F I G U R E  1  Morphometric method 
for establishing the proportion of tumor. A, 
Selection of a 9 mm2 area at the luminal 
surface of a hematoxylin and eosin- stained 
representative section of gastric cancer. A 
total of 300 points are randomly inserted 
into the selected area. B, Annotation of three 
individual points comprised of tumor and 
stroma
A B
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extent of immune cell infiltration per core. If results were 
available for more than one core from the same case, the 
mean value of the cores was calculated. Extensive manual 
quality control checks were carried out at every stage of 
the process. Thus, cores containing normal tissue only or 
a mixture of normal and tumor, with folds or other techni-
cal artifacts were excluded from the final analyses.
2.6 | Statistical analyses
Comparisons between PoT, CD45 staining and clin-
icopathological variables were performed using the 
Mann- Whitney U or Kruskal- Wallis test as appropriate. 
Correlation analyses were performed using Spearman’s 
rank correlation coefficients. Overall survival (OS) time 
was defined as the time from date of surgery to date of 
death or date of last follow- up. The 21 patients who re-
ceived adjuvant UFT was excluded from the survival 
analyses in order to have a homogenously treated study 
population. The relationship between OS and variable of 
interest was evaluated by uni- and multivariate analyses. 
OS curves were calculated using the Kaplan- Meier method 
and compared by the log- rank test. Cox’s proportional haz-
ard model was used to perform univariate and multivariate 
survival analyses. A P- value of less than 0.05 was defined 
as statistically significant. The SPSS software package 
(v11.0J Win, SPSS, Chicago, IL, USA) was used for all 
statistical analyses.
This study was approved by the IRB Committee of the 
Kanagawa Cancer Center.
3 |  RESULTS
3.1 | Clinicopathological data
The selection of the study population for the different analy-
ses steps is illustrated in Figure 2. Median follow- up time after 
surgery was 10.8 years (range: 6.1- 15.4 years). None of the pa-
tients died within 30 days after surgery. The median age was 
65 years (range: 35- 85 years); 153 (66%) patients were male, 
and 78 were female. One hundred and twenty- one patients had 
a distal gastrectomy, 110 a total gastrectomy. The clinicopatho-
logical data of the study population are summarized in Table 1.
3.2 | Proportion of tumor (PoT)at the 
luminal surface
The median proportion of tumor (PoT) of the whole series 
was 33.55% (interquartile range from 0.31% to 88.6%). The 
relationship between clinicopathological variables and PoT 
(high vs low using the median as cutoff) is shown in Table 2. 
PoT was significantly lower in diffuse-type GC compared to 
intestinal- type GC. Venous invasion was more common in 
cancers with high PoT.
3.3 | Survival analyses
There was no significant relationship between PoT and over-
all survival in the whole patient cohort using the median PoT 
(33.55%) as cutoff. Five- year OS rate was 63.5% in patients 
with high PoT tumors and 67.0% in patients with low PoT 
tumors (P = 0.582).
F I G U R E  2  Consort diagram of the 
present study
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We noted that the median PoT was very different 
between intestinal- type (40.51%) and diffuse- type GC 
(29.65%) which prompted us to analyze the relation-
ship with OS stratifying patients by histological tumor 
type. A significant relationship with OS was only seen 
in intestinal- type GC using the intestinal- type median 
PoT (40.51%) as cutoff for analyses. Patients with high 
PoT intestinal- type GC had a significantly shorter 5- 
year OS rate than patients with low PoT intestinal- type 
GC (5- year OS rate high PoT 47.3%, low PoT 77.8%; 
P = 0.0112) (Figure 3). Using Cox proportional hazards 
analysis, high PoT was associated with poorer OS in pa-
tients with intestinal- type GC (hazard ratio (HR): 2.180, 
95% confidence interval (CI): 1.087- 4.372, P = 0.028). 
Multivariate analysis confirmed that high PoT was an 
independent poor prognostic factor when the model was 
adjusted for age, pT, pN, and presence of venous invasion 
(P = 0.023, Table 3). Recurrences were more frequent 
in high PoT intestinal- type GC. When analyzing PoT in 
diffuse- type GC, we used the diffuse- type median PoT 
(29.65%) as cutoff. The 5- year OS rate was not signifi-
cantly different between patients with high PoT diffuse- 
type GC (71.4%) and patients with low PoT diffuse- type 
GC (61.3%), P = 0.2275, Figure 4.
In order to explore potential underlying biological mecha-
nisms of improved survival in patients with low PoT intestinal- 
type GC, we quantified the overall immune response by 
CD45 immunohistochemistry in tissue microarrays using 
automated image analysis. Low PoT was correlated with high 
CD45 in intestinal- type GC (Figure 5, P = 0.035).
Characteristics
All cases
Proportion of tumor  
(cutoff (median): 33.55%)
P value
Low (n = 115) High (n = 116)
n % n % n %
Tumor location
Upper third 68 29.4 39 33.9 29 25.0 0.205
Middle third 92 39.8 46 40.0 46 39.7
Lower third 71 30.8 30 26.1 41 35.3
Tumor size (mm)
Median (range) 55 (15- 212) 55 (15- 200) 55 (18- 212) 0.437
Histological type
Intestinal 78 33.8 30 26.1 48 41.4 0.030
Diffuse 141 61.0 80 69.6 61 52.6
Mucinous 12 5.2 5 4.3 7 6.0
Depth of invasion (pT)
T2/T3 79 34.2 40 34.8 39 33.6 0.838
T4a 152 65.8 75 65.2 77 66.4
Lymph node status (pN)
N0 39 16.9 22 19.1 17 14.7 0.496
N1/N2/N3 192 83.1 93 80.1 99 85.3
Lymphatic invasion
Negative 83 36.0 40 34.8 43 37.1 0.717
Positive 148 64.0 75 65.2 73 62.9
Venous invasion
Negative 60 26.0 41 35.7 19 16.4 0.001
Positive 171 74.0 74 64.3 97 83.6
Adjuvant chemotherapy
Yes 125 54.1 63 54.8 62 53.4 0.839
No 106 45.9 52 45.2 54 46.6
Significant p-values in bold font.
T A B L E  1  Relationship between 
clinicopathological data and proportion of 
tumor (whole series)
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T A B L E  2  Relationship between clinicopathological data and proportion of tumor by histological subtype
Characteristics
All cases
Proportion of tumor (intestinal-type)  
(cutoff (median): 40.51%)
Proportion of tumor (diffuse-type)  
(cutoff (median): 29.65%)
Low (n = 37) High (n = 36)
P- value
Low (n = 62) High (n = 63)
P- valuen (%) n % n % n % n %
Tumor location
Upper third 56 (28.3) 8 21.6 14 38.9 0.249 21 33.9 13 20.6 0.151
Middle third 83 (42.0) 14 37.8 12 33.3 28 45.1 29 46.0
Lower third 59 (29.7) 15 40.6 10 27.8 13 21.0 21 33.3
Tumor size (mm)
Median (range) 50 (18- 95) 58 (20- 120) 0.082 54.5 (15- 200) 56.5 (20- 212) 0.474
Depth of invasion (pT)
T2/T3 67 (33.8) 13 35.1 13 36.1 0.337 22 35.5 19 30.2 0.875
T4a 131 (66.2) 24 64.9 23 63.9 40 64.5 44 69.8
Lymph node status (pN)
N0 36 (18.2) 8 21.6 6 16.7 0.848 13 21.0 9 14.3 0.524
N1/N2/N3 162 (81.8) 29 78.4 30 83.3 49 79.0 54 85.7
Lymphatic invasion
Negative 74 (37.4) 14 37.8 14 38.9 0.926 24 38.7 22 34.9 0.661
Positive 124 (62.6) 23 62.2 22 61.1 38 61.3 41 65.1
Venous invasion
Negative 52 (26.3) 11 29.7 4 11.1 0.049 27 43.5 10 15.9 0.001
Positive 146 (73.7) 26 70.3 32 88.9 35 56.5 53 84.1
Adjuvant chemotherapy
Yes 98 (49.5) 13 35.1 21 58.3 0.047 33 53.2 31 49.2 0.653
No 100 (50.5) 24 64.9 15 41.7 29 46.8 32 50.8
Significant p-values in bold font.
F I G U R E  3  Overall survival curves 
from patients with intestinal-type gastric 
cancer stratified by the proportion of tumor 
(low vs high based on median cutoff)
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4 |  DISCUSSION
In this study, we tested the hypothesis whether proportion of 
tumor (PoT) is related to survival in Japanese gastric cancer 
(GC) patients with locally advanced (TNM stage II/III) GC. 
In contrast to previous studies, we measured PoT at the lu-
minal surface of the tumor as we wanted to evaluate whether 
PoT as a potential biomarker of high risk GC patients may be 
determined early on in patient management, for example, in 
diagnostic endoscopic biopsies.
As one might expect from routine histological GC typing, 
our study showed that the median PoT (eg, tumor cells per 
area tumor) was significantly higher in intestinal- type GC 
which is usually characterized by glandular structures. The 
lower PoT in diffuse- type GC might be related to the loss of 
adhesion between tumor cells in this tumor type which often 
infiltrates the tissue as single cells or small group of cells 
scattered in desmoplastic stroma.
To our surprise, our study showed that high PoT (and 
therefore low proportion of stroma) was a significant inde-
pendent risk factor for poor overall survival in patients with 
intestinal- type GC but not patients with diffuse- type GC. 
Previous studies estimating stroma content in GC did not 
compare survival between patients with different histology 
type. We speculated that the immune cell infiltration, a pa-
rameter known to be related to GC patient survival, might be 
different in different histological subtypes and might depend 
on the extent of intratumoral stroma.22, 23 Our exploratory 
T A B L E  3  Uni- and multivariate Cox proportional hazards analyses of the relationship between clinicopathological factors and overall 
survival in intestinal- type gastric cancer
Characteristics n (%)
Univariate analysis Multivariate analysis
HR 95% CI P- value HR 95% CI P- value
Age
<65y 37 (50.7) 1.000 0.881
≥65y 36 (49.3) 1.053 0.537- 2.065
Site of tumor
Lower or middle third 48 (65.8) 1.000 0.610
Upper third 25 (34.2) 1.238 0.546- 2.808
Tumor size
<55mm 36 (49.3) 1.000 0.530
≥55mm 37 (50.7) 1.242 0.631- 2.446
Depth of invasion (pT)
T2/T3 26 (35.6) 1.000 0.389 1.000 0.096
T4a 47 (64.4) 1.384 0.661- 2.896 1.762 0.904- 3.433
Lymph node status (pN)
N0 14 (19.2) 1.000 0.005 1.000 0.001
N1, N2, N3 59 (80.8) 2.157 1.264- 3.682 2.428 1.434- 4.111
Lymphatic invasion
Negative 28 (38.4) 1.000 0.829
Positive 45 (61.6) 1.079 0.540- 2.157
Venous invasion
Negative 15 (20.5) 1.000 0.591
Positive 58 (79.5) 1.273 0.527- 3.079
Proportion of tumor
Low 37 (50.7) 1.000 0.028 1.000 0.023
High 36 (49.3) 2.180 1.087- 4.372 2.271 1.122- 4.594
Adjuvant chemotherapy
Yes 39 (53.4) 1.000 0.567
No 34 (46.6) 1.219 0.619- 2.399
Significant p-values in bold font.
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study using CD45 as pan- leukocyte marker did confirm a 
correlation between stroma content, histological subtype, and 
CD45- positive immune cells.
However, it is necessary to point out that the three previ-
ous GC studies evaluating the prognostic value of the pro-
portion of stroma,15-17 but also studies investigating the same 
in colorectal cancer18 and other cancers11-13 all describe that 
a high proportion of stroma (eg, low PoT) is related to poor 
survival. Our study showed the opposite for the subgroup 
of intestinal- type GC. The subgroup analysis of the diffuse- 
type GC did not confirm the results from a previous study in 
signet ring cancers,17 although one has to realize that signet 
ring cancers are a specialized subgroup of diffuse- type (or 
poorly cohesive type according to WHO) GC. Thus, a direct 
comparison between the results from signet ring cancers and 
diffuse- type cancers does not appear to be feasible.
There are several differences between the current study 
and the previous studies which may explain the different re-
sults in our current study. We deliberately chose to measure 
the PoT at the luminal surface with the view to assess whether 
the prognostic (or predictive) value of PoT can potentially be 
measured in the diagnostic biopsy setting. All other studies 
measured PoT at the invasive edge, for example, an area which 
would not be accessible to biopsy sampling and/or focused on 
F I G U R E  4  Overall survival curves 
from patients with diffuse type gastric 
cancer stratified by the proportion of tumor 
(low vs high based on median cutoff)
F I G U R E  5  Relationship between proportion of tumor and extent of CD45- positive immune cell infiltration in intestinal-type gastric cancer. 
A, well differentiated intestinal type gastric cancer with low intratumoral stroma content shows relatively sparse infiltration by CD45- positive 
immune cells. (CD45 positive cells = brown, counterstaining hematoxylin = blue). B, moderately differentiated intestinal-type gastric cancer 
with high intratumoral stroma content and extensive infiltration by CD45- positive immune cells. (CD45- positive cells = brown, counterstaining 
hematoxylin = blue)
A B
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assessing areas with lowest tumor cell density whereas we fo-
cused on areas with highest tumor cell density at the opposite 
site of the tumor. Our study selected GC patients with stage 
II or stage III disease, whereas previous studies included pa-
tients with stage I, II, III, and IV. PoT might be related to 
disease stage which we could not reliably investigate in our 
study as patients were all either stage II or stage III disease. 
The study by Lee et al17 suggests that there could be a re-
lationship between PoT and disease stage as in multivariate 
analysis the prognostic significance of the stroma proportion 
was only seen in GC patients with T3/4 disease. Furthermore, 
low PoT was seen in 8% of stage I patients and in up to 69% 
of stage III patients.17 While we measured PoT using a quan-
titative morphometric method, previous investigators simply 
visually estimated PoT which might explain the differences in 
the median PoT between studies.
Our study has some limitations. This study was a retrospec-
tive, single center study from Japan which might have lead to 
patient selection bias. Gastric cancer is known to be heteroge-
neous genetically and phenotypically. The measurement areas 
in the current study were selected in resection specimens based 
on a “presumed” endoscopic biopsy site. Unfortunately, we 
were unable to compare the results from the “virtual” endo-
scopic biopsies with that of the actual diagnostic biopsies of the 
same patients or with that of other parts of the tumor.
In conclusion, this is the first study to identify a sub-
group of patients with intestinal- type gastric cancer which 
has a very poor prognosis. The explorative analysis of the 
correlation between histological subtype, tumor content, and 
immune cell infiltration provides an initial insight into a po-
tential underlying biological mechanism. Our study suggests 
that patient management decisions might not only need to 
consider Lauren’s main histological subtypes (eg, intestinal 
or diffuse) as suggested recently, but also need to consider 
the tumor microenvironment (relative stroma content in com-
bination with immune cell content) in particular in GC pa-
tients with intestinal- type GC. The potential clinical impacts 
of our results warrant validation in a second independent GC 
cohort.
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